|
CA2989963A1
|
|
Delivery systems for controlled drug release
|
|
BR112015030623A2
|
|
cytotoxic agents for cancer treatment
|
|
US2015342975A1
|
|
Anthracycline formulations
|
|
TW200901958A
|
|
Diabetic wound healing
|
|
WO2008070010A2
|
|
Hydroxylamine derivatives for the treatment of stroke
|
|
CN101600434A
|
|
The hydroxylamine derivative of treatment apoplexy
|
|
TW200831479A
|
|
Pharmaceutical compositions and methods for treating diseases
|
|
US2007015720A1
|
|
Modulation of endogenous AICAR levels for the treatment of diabetes and obesity
|
|
HU0303584D0
|
|
Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
|
|
HU0402526A2
|
|
Hydroxylamine derivatives useful in the treatment of vascular diseases, pharmaceutical compositions containing them and use thereof
|
|
CA2455843A1
|
|
Therapeutic delivery compositions and methods of use thereof
|
|
HU0000552A2
|
|
O-(3-piperidino-2-hydroxy-1-propyl)-hydroxymic acid halogenide derivative, its use and medicament containing it
|
|
USRE38558E
|
|
Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
|
|
WO0021543A1
|
|
Method and composition for treating ischemia and sickle cell anemia
|
|
HU9802897D0
|
|
Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
|
|
US5824322A
|
|
Compositions and methods for growth promotion
|
|
EP1181937A2
|
|
Novel vaccine adjuvant and vaccine
|
|
US5674911A
|
|
Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
|
|
US5696298A
|
|
Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
|
|
CA2174122A1
|
|
Therapeutic delivery compositions and methods of use thereof
|
